Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary endpoint of superior A1C reduction vs. placebo at 40 weeks.

Eli Lilly & Co ( ($LLY) ) has risen by 11.35%. Read on to learn why. Eli Lilly & Co has seen a significant rise in its stock price, climbing ...

When the study ended, weight loss did not plateau, suggesting that patients may continue to lose weight, Lilly said.

The pharma giant said its oral GLP-1 drug demonstrated significant efficacy results and a safety profile consistent with its ...

Following the company’s announcement that its diabetes and weight-loss drug helped patients lose up to 16 pounds over 40 ...

Despite worries about an economic slowdown, Netflix continues to prove itself to be a recession-resistant stock.

Eli Lilly’s new obesity and diabetes pill has shown it can lower blood sugar and aid weight loss in a late-stage trial, ...

We recently published a list of 10 Firms End Stronger, Buck Muted Broader Market Trading. In this article, we are going to ...

Eli Lilly stocks displayed a major rise after the announcement of a new oral weight-loss drug that has put pressure on its ...

Eli Lilly surged during Thursday's trading session after promising test results came out of the pharmaceutical company's ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...

One man’s trash may be another man’s treasure, but dumpster diving when investing carries risks. You have to wade through a ...